{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-048184","form_type":"8-K","ticker":"SNTI","cik":"0001854270","company_name":"Senti Biosciences, Inc.","filed_at":"2024-12-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.074372+00:00","generated_at":"2026-05-29T11:49:20.157483+00:00","sec_items":["1.01","5.03","2.03","3.02","3.03","5.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Senti Biosciences raises up to $47.6M in Series A preferred stock and warrants private placement","bullets":["Issued up to 21,157 shares of Series A Convertible Preferred at $2,250/share, with warrants for up to 31.7M common shares at $2.30.","Initial closing of $37.6M (16,713 preferred shares) expected Dec 5, 2024; option for additional $9.9M by Dec 27, 2024.","Series A Preferred carries 18% annual cumulative dividend, convertible into common at $2.25 after stockholder approval.","Director Omid Farokhzad resigned; Frances Schulz (former EY partner) and Donald Tang (Celadon designee) appointed to board.","Net proceeds to fund working capital, R&D, and SENTI-202 program advancement."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-048184","json":"https://secwatch.observer/filing/0001140361-24-048184.json","markdown":"https://secwatch.observer/filing/0001140361-24-048184.md","text":"https://secwatch.observer/filing/0001140361-24-048184.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1854270/000114036124048184/0001140361-24-048184-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1854270/000114036124048184/ef20039400_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T11:49:20.157483+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"06595b7955","claim":"Frances D. Schulz was appointed as Director at Senti Biosciences, Inc..","evidence_excerpt":"On December 2, 2024, upon the recommendation of its Nominating and Corporate Governance Committee, the Board unanimously appointed Frances D. Schulz to fill a newly created vacancy on the Board resulting from the resignation of Dr. Farokhzad, such appointment to be effective upon the initial closing of the Offering.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1854270/000114036124048184/0001140361-24-048184-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}]},{"claim_id":"20b1a5cb8e","claim":"Omid Farokhzad resigned as Director at Senti Biosciences, Inc..","evidence_excerpt":"On November 25, 2024, Omid Farokhzad, M.D., a member of the Board and the Audit Committee of the Board, notified the Board of his resignation as a director of the Company and all committees thereof, effective November 25, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1854270/000114036124048184/0001140361-24-048184-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}